Key Takeaways
- Record revenue, pricing-led: Consolidated revenue hit an all-time high of ₹829 crores, driven by a 16% YoY realization jump on top of 5% volume growth, as geopolitical disruption pushed API customers to prioritize reliable supply.
- Margins at a six-year peak: EBITDA margin reached 16.6%, the highest in nearly six years, powered by structural gains from backward integration, product mix improvement, and the Saykha Methylamines facility scaling up.
- Formulations delivered an exceptional quarter: The segment grew 58% YoY to ₹130 crores with a 28% EBITDA margin, fueled by a 73% export surge as products commercialized in newer regulated and emerging markets.
- Structural gains are durable, pricing is not: Management says the backward integration and mix benefits will stay even as the pricing environment normalizes, and it is guiding conservatively to a 15% sustainable EBITDA margin versus the 16.6% achieved this quarter.
- What to watch next quarter: Whether formulation purchasers accept the new pricing normal and restart volume buying, the pace of the US oncology product ramp, and any progress on the anti-dumping duty petition for salicylic acid.
Revenue & Pricing Dynamics
- API segment led the quarter: Revenue grew 17% YoY to ₹605 crores, with price growth of roughly 17 to 18% and volume growth of about 5%. The pricing strength began with gas-based products after the March conflict and has now extended to crude-linked products.
- Volume growth was muted by buyer caution: H1 volume growth was only 3 to 5% because formulation purchasers refrained from overstocking amid sudden, geopolitically driven price spikes. Management describes this as a waiting game until buyers accept a new normal.
- Gross margin paradox: When API and specialty chemical rates rise, gross contribution increases in absolute terms but gross contribution margin decreases due to the base effect inherent in the cost-plus formula the business runs on.
- Standalone export weakness: Domestic revenue grew 43% YoY while export revenue declined 5% YoY on a standalone basis, a divergence management did not explicitly reconcile on the call.
- Inventory discipline: Management will not stock up on raw materials at elevated prices, aiming instead to match raw material booking with sales booking to avoid losses if the market turns.
Adhish Patil: "Typically, the purchasing people at the formulation side, they try to refrain overstocking the product because the prices have suddenly gone up due to geopolitical reasons. So, there is a waiting game here. So, once they start believing that this is a new normal, then the volume growth and the demand should start to come in."
Formulations: The Breakout Quarter
- Exports drove the surge: Formulation exports rose 73% YoY, accounting for 74% of total formulation sales in Q2, as products under registration in regulated and emerging markets began commercializing.
- Revenue sustainability: Management believes a similar revenue level is sustainable for the rest of the year, supported by an export order book covering roughly four months and ongoing entry into multiple markets with multiple products.
- Margin sustainability is more cautious: The 28% EBITDA margin is exceptional and tied to the current order book. Management is conservative, assuming a steady-state formulation margin of 20%, though if orders keep coming, margins should sustain at least in the early 20s.
- ₹1,000 crore aspiration pulled forward: Management believes the ₹1,000 crore formulation revenue target is achievable earlier than the published timeline, helped by a brownfield expansion doubling oral solid dosage capacity by mid-next year and the oncology facility ramp.
- Oncology ramp beginning: A recently launched US oncology product made a small contribution in Q2, with revenue expected to increase in 3 to 6 months. Another ANDA is due for approval in the next few months, and 4 to 5 more oncology products will be filed in the rolling 12 months. Oncology carries slightly higher gross margins than the rest of the formulation portfolio.
Vishwa Savla: "So, while this was an exceptional quarter, but we believe that now with our entry into newer markets and newer products, we will be able to sustain a similar level of revenue."
Margin Structure & Sustainability
- Six-year high with structural underpinnings: The 16.6% consolidated EBITDA margin was the highest in nearly six years, driven by structural gains in product mix, backward integration, and cost efficiency from the Saykha Methylamines facility.
- Conservative guidance at 15%: Despite the strong print, management feels 15% EBITDA margin should be sustainable, treating the Q2 outperformance as a buffer rather than a new baseline.
- Standalone margin levers: Roughly 50 bps of margin improvement came from gross contribution increases, with the rest from manufacturing cost reduction. Operational energy optimization projects are underway, and solar projects will begin contributing from the December quarter.
- Backward integration paying off: The Methylamines plant at Saykha operated at roughly 72% utilization, and captive consumption of the antidiabetic portfolio rose to about 85%, giving better control over cost, quality, and availability of inputs for metformin.
Adhish Patil: "These gains in product mix, backward integration and cost efficiency are structural and they will stay with us even as the pricing environment normalizes over time."
Capacity Expansion & Capex Pipeline
| Project | Details | Timeline |
|---|---|---|
| Tarapur USFDA block expansion | Adjacent block with three new multipurpose plants for regulated markets, more than doubling capacity | Commercial production targeted end of FY29 (18 to 20 months) |
| Sarigam metformin capacity | Increase from 1,400 to 1,700 tonnes/month | Commercialization early FY28 |
| Sarigam USFDA metformin block | Dedicated 500 tonnes/month block; USFDA DMFs under preparation; expected to open US and EU markets | End of FY28 |
| Baddi brownfield expansion | Adjacent plot to nearly double oral solid dosage manufacturing capacity | Mid-next year |
| Tarapur methyl salicylate | Technical grade production started; roughly 85 tonnes manufactured in Q2 FY27 | Already operational |
- Cash flow supports the build-out: H1 operating cash flow was roughly ₹90 crores, split approximately equally between standalone and formulation, providing internal funding capacity for the capex program.
Strategic Direction & Regulatory Catalysts
- Five-to-seven-year business plan in development: Management is working on a plan that introduces a mixed bucket of molecules, combining volume-led products where the company's strength lies with more niche APIs, plus a CDMO platform for intermediates and specialty chemicals. A clearer picture on capex and capital assignment is expected in 4 to 5 months.
- Regulatory market push: The plan includes increasing the footprint in regulated markets for existing molecules to improve and stabilize margins, with the USFDA-compliant metformin block and Tarapur multipurpose facility as key enablers.
- Anti-dumping duty on salicylic acid: The company will submit a September report with an additional nine months of data. The DGTR is expected to intimate initiation before the December year-end, with the process then taking another 3 to 6 months after initiation to complete.
- Oncology as a long-term anchor: Management targets oncology contributing late 30s to early 40s percent of revenue by FY30, with a widespread global strategy covering the US, EU, UK, Latin America, Middle East, and Asian markets.
- R&D investment rising: The company plans to invest quite heavily in R&D within the formulation division, supporting the shift toward complex, regulated-market products.
Adhish Patil: "So, going forward, we are actually working on a business plan for the next, you can say five to seven years, which includes introducing a mixed bucket of molecules. Some of them would be similar to what we do, where our strength lies. Some of them would be a bit more niche molecules in APIs. And we are also trying to develop competencies on a CDMO platform."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated EBITDA margin | 15% sustainable | Ongoing |
| Formulation revenue | Current level sustainable for rest of year | FY27 |
| Formulation margin | Steady-state 20% (versus 28% in Q2) | Beyond current 4-month order book |
| Volume growth | High single-digit possible if buyers accept new pricing normal | Conditional on buyer behavior |
| Tarapur USFDA block | Commercial production | End of FY29 |
| Sarigam metformin expansion | 1,700 tonnes/month | Early FY28 |
| Sarigam USFDA metformin block | 500 tonnes/month dedicated block | End of FY28 |
| Baddi formulation expansion | Double oral solid dosage capacity | Mid-next year |
| US oncology revenue ramp | Increase from small Q2 contribution | 3 to 6 months |
| Oncology ANDA pipeline | One more approval in next few months; 4 to 5 filings in rolling 12 months | Next 12 months |
| Anti-dumping duty process | DGTR initiation before December year-end; completion in 3 to 6 months thereafter | Initiation by Dec 2025; completion mid-2026 |
| Complex API/CDMO capex plan | Clearer picture on capex and capital assignment | 4 to 5 months |
| Oncology revenue target | Late 30s to early 40s percent of revenue | FY30 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹829 cr, +27% YoY |
| Consolidated EBITDA | ₹138 cr, +63% YoY |
| Consolidated EBITDA margin | 16.6%, +370 bps YoY, highest in nearly 6 years |
| Consolidated PAT | ₹83 cr, +83% YoY |
| Consolidated PAT margin | 10.0%, +310 bps YoY |
| Standalone revenue | ₹709 cr, +22% YoY |
| Standalone domestic revenue growth | +43% YoY |
| Standalone export revenue growth | -5% YoY |
| API segment revenue | ₹605 cr, +17% YoY |
| Specialty chemicals revenue | ₹72 cr, +92% YoY |
| Formulations revenue | ₹130 cr, +58% YoY; exports contributed 74% |
| Formulations EBITDA margin | ~28%, exceptional due to export orders |
| Standalone volume growth (API + spec chem) | ~5% YoY |
| Standalone realization growth | ~17–18% YoY |
| Methylamines facility utilization (Saykha) | ~72% |
| Captive consumption of antidiabetic portfolio | ~85% |
| Technical grade methyl salicylate produced (Tarapur) | ~85 tonnes in the quarter |
| Formulations pending export order book | ~4 months visibility |
| H1 FY27 operating cash flow | ~₹90 cr, standalone and formulation roughly equal |